Trials of interferon beta-1b
The first trials of interferon in multiple sclerosis used recombinant interferon beta-1b.
Interferon beta-1b differs from the human cytokine in two ways:
- has an aminoacid substitution at one position
- is non-glycosylated
Patients treated with the high dose of 8 MIU subcutanesouly on alternate days had the following significant benefits:
- 34% reduction in the relapse rate
- marked reduction in disease burden as assessed by T2-weighted MRI imaging after two years
The trials with interferon beta-1b did not show a significant reduction in accumulated disability.
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.